Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading

Diagnostic Microbiology and Infectious Disease

Volumn 38, Issue 2, 2000, Pages 101-107

  Uzun, Omrum ^a   Arikan, Sevtap ^a   Kocagöz, Sesin ^a   Sancak, Banu ^a   Unal, Serhat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TRICHOSPORON; UNIVERSITY HOSPITAL; YEAST;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HOSPITALS, UNIVERSITY; HUMAN; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; REFERENCE STANDARDS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRIAZOLES; TRICHOSPORON; TURKEY;

EID: 0033780545     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00177-2     Document Type: Article

References (41)

1. Anaissie E., Paetznick V., Bodey G.P. Fluconazole susceptibility testing of Candida albicans Microtiter method that is independent of inoculum size, temperature, and time of reading . Antimicrob Agents Chemother. 35:1991;1641-1646.
2. Anaissie E.J., Paetznick V.L., Ensign L.G., et al. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation An eight-center collaborative study . Antimicrob Agents Chemother. 40:1996;2387-2391.
3. Arikan S., Gür D., Akova M. Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients. Mycoses. 40:1997;291-296.
4. Barry A.L., Brown S.D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496], and fluconazole) against Candida species. Antimicrob Agents Chemother. 40:1996;1948-1949.
5. Belanger P., Nast C.C., Fratti R., Sanati H., Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and-resistant Candida species. Antimicrob Agents Chemother. 41:1997;1840-1842.
6. Bodey, G. P. (1984). Candidiasis in cancer patients. J Am Med 77 (Suppl. 4D): 13-19.
7. Bodey, G. P. (1992). Azole antifungal agents. Clin Infect Dis 14 (Suppl. 1):161-169.
8. Boken D.J., Swindells S., Rinaldi M.G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 17:1993;1018-1021.
9. Chavez M., Bernal S., Valverde A., Gutierrez M.J., Quindos G., Martin Mazuelos E. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. Isolates from HIV-infected patients. J. Antimicrob Chemother. 44:1999;697-700.
10. Cuenca-Estrella M., Diaz-Guerra T.M., Mellado E., Monzon A., Rodriguez-Tudela J.L. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis. 18:1999;432-435.
11. De Sévaux R.G.L., Kullberg B.J., Verweij P.E., van de Nes J.A.P., Meis J.F.G.M., van der Meer J.W.M. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease cure with voriconazole . Clin Infect Dis. 26:1998;996-997.
12. Espinel-Ingroff A., Dawson K., Pfaller M.A., et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 39:1995;314-319.
13. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 36:1998;198-202.
14. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-118, p.484. American Society for Microbiology, Washington, D.C.
15. Gallis H.A., Drew R., Pickard W.W. Amphotericin B 30 years of clinical experience . Rev Infect Dis. 12:1990;308-329.
16. Hegener P., Troke P.F., Fatkenheuer G., Diehl V., Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS. 12:1998;2227-2228. (Letter).
17. Holm, S. E., Tornqvist, I. O., & Cars, O. (1990). Paradoxical effects of antibiotics. Scand J Infect Dis 74 (Suppl):113-117.
18. Kauffman C.A., Zarins L.T. Colorimetric method for susceptibility testing of voriconazole and other triazoles against Candida species. Mycoses. 42:1999;539-542.
19. rd ed. ASM Press, Washington, D.C.
20. Law D., Moore C.B., Denning D.W. Amphotericin B resistance testing of Candida spp. A comparison of methods . J Antimicrob Chemother. 40:1997;109-112.
21. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-19b, p.456. American Society for Microbiology, Washington, D.C.
22. Lozano-Chiu M., Arikan S., Paetznick V.L., Anaissie E.J., Rex J.H. Optimizing voriconazole susceptibility testing of Candida Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility . J Clin Microbiol. 37:1999;2755-2759.
23. Marco F., Pfaller M.A., Messer S., Jones R.N. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 42:1998;161-163.
24. McGinnis M.R., Pasarell L., Sutton D.A., Fothergill A.W., Cooper C.R. Jr, Rinaldi M.G. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 41:1997;1832-1834.
25. Meunier F. Fungal infections in cancer patients. Cancer Invest. 9:1991;151-158.
26. National Committee for Clinical Laboratory Standards. (1997). Reference method for broth dilution antifungal susceptibility testing of yeasts:: Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
27. Nguyen M.H., Yu C.Y. Voriconazole against fluconazole-susceptible and resistant candida isolates in vitro efficacy compared with that of itraconazole and ketoconazole . J Antimicrob Chemother. 42:1998;253-256.
28. Nguyen M.H., Clancy C.J., Yu V.L., et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 177:1998;425-430.
29. Nguyen M.H., Yu C.Y. Influence of inoculation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. J Clin Microbiol. 37:1998;141-145.
30. Pfaller M.A., Messer S.A., Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J Clin Microbiol. 33:1995;1094-1097.
31. Pfaller M.A., Messer S.A., Hollis R.J., et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother. 42:1998;3242-3244.
32. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents . Diagn Microbiol Infect Dis. 35:1999;19-25.
33. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 39:1995;1-8.
34. Rex J.H., Cooper C.R., Merz W.G. Jr, Galgiani J.N., Anaissie E.J. Detection of amphotericin-B resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 39:1995;906-909.
35. Rex J.H., Nelson P.W., Paetznick V.L., Lozano-Chiu M., Espinel-Ingroff A., Anaissie E.J. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidasis. Antimicrob Agents Chemother. 42:1998;129-134.
36. Ruhnke M., Schmidt-Westhausen A., Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients with Human Immunodeficiency Virus infection. Antimicrob Agents Chemother. 41:1997;575-577.
37. Sanglard D., Kuchler K., Ischer F., Pagani J-L, Monod M., Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 39:1995;2378-2386.
38. St. Germain G. Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother. 34:1990;2304-2306.
39. Uzun, O., & Anaissie, E. J. (1996). Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis 22 (Suppl. 2): 95-101.
40. Uzun O., Kocagoz S., Cetinkaya Y., Arikan S., Unal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 41:1997;1156-1157.
41. Van't Hek L.G., Verweij P.E., Weemaes C.M., van Dalen R., Yntema J.B., Meis J.F. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Resp Crit Care Med. 157:1998;1694-1696.